Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | PRKCG | P05129 | 1/20 | 0.30 |
| ▸ | PRKCB | P05771 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCH | P24723 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7929454 | 0.83 | — | — | |
| SCHEMBL14755325 | 0.81 | PLA2G2C (0.35) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL2632269 | 0.81 | PLA2G2C (0.35) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL13419618 | 0.79 | PRKD3 (0.46) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL12391178 | 0.79 | — | — | |
| SCHEMBL8143953 | 0.78 | TSHR (0.41) | LPAR1LPAR3LPAR2USP2PRKD3 | |
| SCHEMBL17794227 | 0.77 | PLA2G2C (0.36) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL17794223 | 0.75 | PLA2G2C (0.37) | PLA2G2CLPAR1LPAR3LPAR2USP2 | |
| SCHEMBL28357447 | 0.75 | TSHR (0.43) | LPAR1LPAR3LPAR2USP2PRKD3 | |
| SCHEMBL15821116 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016085780-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| WO-2010038686-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207723-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | PLA2G2C 1970/4885LPAR1 965/4885LPAR3 969/4885 |
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, PSEN1 | PLA2G2C 1652/4885LPAR1 2074/4885LPAR3 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.